CMG Pharmaceutical Co., Ltd. (058820.KQ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	115.7B	105.2B	99.1B	93.9B	82.2B
Cost of Revenue	52.1B	45.8B	53.4B	50.2B	41.3B
Gross Profit	63.6B	59.4B	45.7B	43.7B	40.9B
Operating Expenses
R&D Expense	1.3B	1.8B	1.5B	2.2B	3.3B
SG&A Expense	55.7B	46.3B	20.8B	35.7B	32.1B
General & Admin Expense	701.5M	1.2B	3.0B	2.9B	3.1B
Selling & Marketing Expense	38.1B	45.0B	17.9B	15.9B	14.1B
Other Expenses	10.6B	15.1B	22.4B	—	2.5B
Total Operating Expenses	67.2B	63.1B	44.7B	37.9B	37.9B
Cost and Expenses	119.3B	108.9B	98.1B	88.2B	79.2B
Operating Income (EBIT)	(3.6B)	(3.7B)	1.0B	5.7B	3.0B
Non-Operating
Interest Income	1.9B	2.9B	3.1B	3.8B	2.0B
Interest Expense	1.0B	3.2B	2.5B	79.5M	15.3M
Net Interest Income	890.5M	(231.1M)	618.0M	3.7B	1.9B
Other Non-Op Income/Expense	8.5B	(8.0B)	1.9B	3.7B	(4.2B)
Non-Operating Income (excl Interest)	(367.7M)	—	(4.4B)	2.7B	4.2B
EBT (Pre-Tax Income)	4.8B	(11.6B)	2.9B	6.7B	(1.3B)
Income Tax Expense	(914.2M)	(2.7B)	185.6M	275.7M	(867.0M)
Bottom Line
Net Income	5.8B	(9.0B)	2.7B	6.5B	(388.1M)
Earnings from Cont. Ops	5.8B	(9.0B)	2.7B	6.5B	(388.1M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	5.8B	(9.0B)	2.7B	6.5B	(388.1M)
Per Share
Basic EPS	₩39	(₩61)	₩19	₩46	(₩14)
Diluted EPS	₩39	(₩61)	₩5	₩46	(₩14)
Revenue Per Share	₩782	₩712	₩714	₩3,400	₩2,956
Shares
Basic Shares Outstanding	147.9M	147.8M	138.9M	27.6M	27.8M
Diluted Shares Outstanding	147.9M	147.8M	157.1M	27.6M	27.8M
Profitability Metrics
EBITDA	4.2B	(610.4M)	8.7B	5.6B	5.3B
D&A	2.7B	3.1B	3.3B	2.6B	2.3B
EBIT	1.5B	(3.7B)	5.4B	3.0B	3.0B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026